Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-daratumumab Imaging in Multiple Myeloma
NCT03665155Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2018
- Primary completion
- Apr 2020
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zirconium Zr-89-DFO-daratumumab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Average Absorbed Radiation Dose Estimates for Normal Tissues up to 19 months. Started Sep 2018; status: completed.
02
Drugs
zirconium Zr-89-DFO-daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03665155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665155.